The Federal Trade Commission alleges that pharmacy benefits managers prioritized high rebates from drug makers for insulin over lower prices for consumers, leading to inflated out-of-pocket costs.
Copyright 2024 NPR
Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.